Loading
A phase 1/2 trial of SKB105 for injection Monotherapy in advanced solid tumours, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.
SKB105 for Injection in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07380386 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 256 participants planned, started 2026-03-05 and due to reach its primary completion in 2029-12-31. Interventions recorded: SKB105 for injection Monotherapy.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/